−$3.15 (27.19%) At close $8.42 · Today
☾After Hours +$0.31 (3.69%) Nov 2, 4:47 PM ET
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
No direct coverage yet · Showing articles that mention CMPS
The Motley Fool
1 Reason Compass Pathways Is Worth a Second Look This MonthCompass Pathways is developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression. With positive Phase 3 trial results and an FDA Commissioner's National Priority Voucher, the company expects to complete its FDA application by end of 2026, potentially leading to approval in early 2027. Analysts project 95% upside from current $12 share price to average target of $23.75.
Headlines open the publisher's site.
